Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01004 ointment in atopic dermatitis
NCT07071610Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LNK01004 in atopic dermatitis (AD) (3 arms), sponsored by Lynk Pharmaceuticals. Primary endpoint: Mean Percentage Change From Baseline in Eczema Area and Severity Index at 8 weeks. Started Mar 2025; status: completed.
02
Drugs
LNK01004
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07071610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071610.